stem cell therapy and cell therapy is a new emerging way in medicine and in cardiovascular diseases.

2. Cell Therapy For Cardiovascular Diseases

3. Supervisors: Prof. Dr. Ahmed Mohamed ZaghlolDarwish Professor of Cardiology Faculty of Medicine Tanta University Prof. Dr. Magdy Mohamed El-Masry Professor of Cardiology Faculty of Medicine Tanta University Prof. Dr. SamiaMahmoudSharf El-deen Professor of Cardiology Faculty of Medicine Tanta University

4. Definitions

6. Capacity of clonal expansion.

7. Multipotant differentiation..

9. Can differentiate into a specific type of cells.

17. Bone Marrow–Derived Stem/Progenitor Cells:

18. Hematopoietic stem cells (HSCs).

19. Mesenchymal (stromal) stem cells (MSCs).

20. Endothelial progenitor cells.

21. Umbilical Cord Blood Cells.

22. Resident cardiac stem/progenitor cells.

23. Adipose-derived stem cells.

25. Bone Marrow–Derived Stem/Progenitor Cells:

26. Hematopoietic stem cells (HSCs).

27. Mesenchymal (stromal) stem cells (MSCs).

28. Endothelial progenitor cells.

29. Umbilical Cord Blood Cells.

30. Resident cardiac stem/progenitor cells.

31. Adipose-derived stem cells.

33. Bone Marrow–Derived Stem/Progenitor Cells:

34. Hematopoietic stem cells (HSCs).

35. Mesenchymal (stromal) stem cells (MSCs).

36. Endothelial progenitor cells.

37. Umbilical Cord Blood Cells.

38. Resident cardiac stem/progenitor cells.

39. Adipose-derived stem cells.

42. Bone Marrow–Derived Stem/Progenitor Cells:

43. Hematopoietic stem cells (HSCs).

44. Mesenchymal (stromal) stem cells (MSCs).

45. Endothelial progenitor cells.

46. Umbilical Cord Blood Cells.

47. Resident cardiac stem/progenitor cells.

48. Adipose-derived stem cells.

50. Bone Marrow–Derived Stem/Progenitor Cells:

51. Hematopoietic stem cells (HSCs).

52. Mesenchymal (stromal) stem cells (MSCs).

53. Endothelial progenitor cells.

54. Umbilical Cord Blood Cells.

55. Resident cardiac stem/progenitor cells.

56. Adipose-derived stem cells.

59. Bone Marrow–Derived Stem/Progenitor Cells:

60. Hematopoietic stem cells (HSCs).

61. Mesenchymal (stromal) stem cells (MSCs).

62. Endothelial progenitor cells.

63. Umbilical Cord Blood Cells.

64. Resident cardiac stem/progenitor cells.

65. Adipose-derived stem cells.

68. Bone Marrow–Derived Stem/Progenitor Cells:

69. Hematopoietic stem cells (HSCs).

70. Mesenchymal (stromal) stem cells (MSCs).

71. Endothelial progenitor cells.

72. Umbilical Cord Blood Cells.

73. Resident cardiac stem/progenitor cells.

74. Adipose-derived stem cells.

77. Bone Marrow–Derived Stem/Progenitor Cells:

78. Hematopoietic stem cells (HSCs).

79. Mesenchymal (stromal) stem cells (MSCs).

80. Endothelial progenitor cells.

81. Umbilical Cord Blood Cells.

82. Resident cardiac stem/progenitor cells.

83. Adipose-derived stem cells.

85. This regeneration capacity are likely due to presence of defined pool of resident progenitor cells.

88. Bone Marrow–Derived Stem/Progenitor Cells:

89. Hematopoietic stem cells (HSCs).

90. Mesenchymal (stromal) stem cells (MSCs).

91. Endothelial progenitor cells.

92. Umbilical Cord Blood Cells.

93. Resident cardiac stem/progenitor cells.

94. Adipose-derived stem cells.

97. Bone Marrow–Derived Stem/Progenitor Cells:

98. Hematopoietic stem cells (HSCs).

99. Mesenchymal (stromal) stem cells (MSCs).

100. Endothelial progenitor cells.

101. Umbilical Cord Blood Cells.

102. Resident cardiac stem/progenitor cells.

103. Adipose-derived stem cells.

105. Methods Of Cell Delivery

107. Easily performed.

108. Cost benefit ratio within range.

109. Applicable across a wide range of clinical scenarios

112. Need for concomitant open-heart surgery.

115. It can be performed at the same time of (PCI).

116. Disadvantages:Not suitable for all cell types as larger cells as MSCs may occlude the Microcirculation.

119. Can easily be repeated if necessary.

120. Disadvantage:low percentage of cells delivered.

122. The needle is directed toward the myocardium through which cells and drugs can be injected.

124. Cell therapy seems to act through three mechanistic pathways: Differentiation into cardiomyocytes. Cell Fusion with host cardiomyocytes. Paracrine effects.

126. high level of circulating stem cells.

127. Organ damage

128. Signaling factors as G-CSF, VEGF.

129. cell-to-cell contact with cardiomyocytes.

132. These factors: Inhibit cardiomyocyte apoptosis. Enhance angiogenesis. Rescue injured myocytes. Inhibit pathologic remodeling.

133. Cell Therapy for Acute Myocardial Infarction

137. Cell Therapy in End-stage Ischemic Heart Disease With no Further Revascularization Options

139. Most trials have been small phase 1 studies and shown improved perfusion and myocardial function.

142. Two main cells was involved in HF cell therapy trials:

143. Skeletal Myoblasts.

147. Role of cell therapy in PAH either:

148. Contributing to blood vessel thickening (remodeling) and blockage in PAH.

154. Thank you